Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Figure 2

Kaplan-Meyer plot of cumulative proportion of patients remaining free from relapse by prior exposure to natalizumab over time from start of fingolimod therapy.